
Pattern: Developing smarter, faster diagnostic drugs through a dedicated team of visionaries.
Pattern Bioscience, founded with a mission to revolutionize the field of diagnostics, focuses on developing faster and more precise diagnostic tools to combat the misuse of antibiotics in hospitals. The company leverages single-cell microbiology to decode the metabolic patterns of individual bacterial cells, providing rapid and definitive identification and antibiotic susceptibility testing (ID/AST) results within hours. This approach aims to significantly reduce the 50% rate of unnecessary or inappropriate antibiotic prescriptions in hospital settings.
Notable figures affiliated with Pattern Bioscience include a team of leading scientists and industry visionaries dedicated to addressing global health challenges. The company has attracted significant investment from prominent healthcare and biotech investors. Key achievements include the development of their proprietary single-cell microbiology technology, which has shown promise in clinical settings for improving patient outcomes and reducing antibiotic resistance. Pattern Bioscience's impact is marked by its potential to transform hospital practices and enhance the precision of infectious disease treatment globally.

Pattern Genomics

BioAmp diagnostics
bioampdx.com

Specific Diagnostics

MicrobeDx
microbedx.com

Cobio Diagnostics
cobio.co

3i Diagnostics
3idx.com

Day Zero Diagnostics

Astek Diagnostics
astekdx.com

Aperiomics
Microbial Pulse Diagnostics

Prompt Diagnostics
prompt-dx.com

Probius
probius.bio

OmniVis

Phoresa

Thread Bioscience
threadb.com
Companies similar to Pattern Bioscience include Pattern Genomics, BioAmp diagnostics, Specific Diagnostics and MicrobeDx.
Pattern Bioscience was founded in 2016.
Pattern Bioscience's headquarters is located in Austin, TX, US.
Pattern Bioscience's most recent funding round was for $28.7M (USD) in April 2023.
As of Apr 27, 2023, Pattern Bioscience has raised a total of $54.6M (USD).
Pattern Bioscience has 70 employees as of Feb 5, 2024.